QTX-2101, an oral arsenic trioxide, received FDA fast track designation for acute promyelocytic leukemia, aiming to simplify ...

Quetzal Therapeutics, a biopharmaceutical company focused on developing treatments for rare diseases, announced that the U.S.

The Food and Drug Administration (FDA) has granted Fast Track designation to QTX-2101, an oral formulation of arsenic trioxide, for the treatment of acute promyelocytic leukemia (APL), an aggressive ...

Amgen acquires Dark Blue Therapeutics to fight Acute Myeloid Leukemia. See how this $840M deal aims to deliver first-in-class ...

Acute promyelocytic leukaemia (APL) represents a unique and once highly fatal subtype of acute myeloid leukaemia that is now considered among the most curable forms of haematological malignancies.

APOLLO: Optimizing the Treatment of High-Risk Acute Promyelocytic Leukemia With All-Trans Retinoic Acid and Arsenic Trioxide While Minimizing the Role of Chemotherapy The following represents ...

Ravandi: Just like you said, APL is a relatively uncommon subset of acute myeloid leukemia, but I think of it as a sort of a poster child for all the other subsets because over the past two or two and ...

Researchers at the LKS Faculty of Medicine of the University of Hong Kong (HKUMed) have invented an oral formulation of arsenic trioxide (Oral-ATO; ARSENOL) for the treatment of acute promyelocytic ...

Combining all-trans retinoic acid (ATRA) with arsenic trioxide (ATO) and idarubicin significantly improved event-free survival (EFS) compared with the standard treatment of ATRA and ...

A case study published by researchers at Johns Hopkins University showed that optical genome mapping (OGM) detected a structural variant that was missed by karyotyping and non-informative by FISH, ...

Researchers at Zhejiang University School of Medicine have identified a single point mutation in the normal PML gene that can block the effect of arsenic trioxide, a frontline drug for acute ...